Progress of biomarkers in peripheral blood of immunotherapy for gastric cancer
ZHAO Wenhui
WANG Mengxiang
ZHOU Min
CHEN Yan
Abstract：Immunotherapy represented by immune checkpoint inhibitors(ICIs)has deeply changed the treatment paradigm of gastric cancer(GC).Microsatellite instability(MSI),EBV infection,and tumor tissue programmed death receptor ligand 1(PD-L1)expression levels can effectively predict the efficacy of immunotherapy for GC,but there are still some patients who do not benefit or experience immune-related adverse effects,so there is an urgent need to explore more predictive biomarkers for selecting the immunization beneficiary population.Tissue specimens are invasive and difficult to overcome the spatiotemporal heterogeneity of tumors,while peripheral blood markers are noninvasive and reproducible,and can cover both tumor and host information,which can help to improve the strategy of patient stratification.In this paper,we summarize the research progress of peripheral blood biomarkers related to GC immune checkpoint inhibitor therapy from two major aspects,namely,tumor-and host-related biomarkers,with the aim of providing certain references for the selection of immunotherapy and the prediction of therapeutic efficacy in gastric cancer patients.
Keywords：Gastric cancerImmune checkpoint inhibitorsImmunotherapyPeripheral blood biomarkersResearch progress
Publication Date：2025-02-19
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：11( 87-97 )